Muscarinic M2 and M3 receptor function in smooth muscle

Proceedings of the Western Pharmacology Society

Volumn 39, Issue , 1996, Pages 57-60

  Eglen, R M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 [[4 [4 (DIETHYLAMINO)BUTYL] 1 PIPERIDYL]ACETYL] 5,11 DIHYDRO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPIN 6 ONE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ADENYLATE CYCLASE; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; GALLAMINE; HEXAHYDROSILADIFENIDOL DERIVATIVE; HIMBACINE; ISOPRENALINE; METHOCTRAMINE; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; NUVENZEPINE; OTENZEPAD; PHOSPHATIDYLINOSITIDE; PIRENZEPINE; PROTEIN KINASE C; RECEPTOR SUBTYPE; TELENZEPINE; VAMICAMIDE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG RECEPTOR BINDING; HUMAN; IRRITABLE COLON; MOLECULAR INTERACTION; NONHUMAN; RECEPTOR AFFINITY; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE TONE; URGE INCONTINENCE; ANIMAL; DRUG ANTAGONISM; MUSCLE CONTRACTION; MUSCLE RELAXATION; PHYSIOLOGY; REVIEW; SMOOTH MUSCLE;

ANIMALS; CYCLIC AMP; HUMANS; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC;

EID: 0029658797     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D & Jones SV: Prog Brain Res 98: 121 (1993).
2. Caulfield MD: Pharmacol Therap 58: 319 (1993).
3. Hosey MM: FASEB J, 6: 845 (1992).
4. Hulme EC, Birdsall NJM & Buckley NJ: Ann Rev Pharmacol Toxicol 30: 633 (1990).
5. Dörje F, Wess J, Lambrecht G, Tacke R, Mutschier E & Brann MR: J Pharmacol Exp Therap 256: 727 (1991).
6. Guo ZD, Kameyama K, Rinken A & Haga T: J Pharmacol Exp Therap 274: 378 (1995).
7. Grimm U, Moser U, Mutschier E & Lambrecht G: Pharmazie 49: 711 (1994).
8. Moltzen EK & Bjornholm B: Drugs of the Future 20: 37 (1995).
9. Kenakin TP, Bond RA & Bonner TI: Pharmacol Rev 44: 351 (1992).
10. Eglen RM, Reddy H & Watson N: Int J Biochem 26: 1357 (1994).
11. Schwarte RD, Davis RE, JaenJC, Spencer CJ, Tecle H & Thomas AJ: Life Sei 52: 465 (1993).
12. Richards MH: Biochem Pharmacol 42: 1645 (1991).
13. Wallis RM: Life Sei 56: 861 (1995).
14. Ehlert FJ & Thomas EA: Life Sei 56: 965 (1995).
15. Eglen RM, Reddy H, Watson N & Challiss RAJ: Trends Pharmacol Sei 15: 114 (1994).
16. Eglen RM & Whiting RL: J Auton Pharmacol 19: 233 (1990).
17. Hammarström AKM, Parkington HC & Coleman HA: Br J Pharmacol 115: 717 (1995).
18. Eglen RM, Harris GC, Taylor M, Pfister JR & Whiting RL: N-S Arch Pharmacol 344: 29 (1992).
19. Hua XY, Back SM & Yaksh TL: Neuroreport 5: 2133 (1994).
20. Kachur JF, Sturm BL, Gaginella TS & Noronha-Blob L: Mol Pharmacol 38: 836 (1990).
21. Choo LK & Mitchelson FJ: J Pharm Pharmacol 37: 656 (1985).
22. Roffel AF, Elzinga CRS, Amsterdam ROM, van de Zeeuw RA & Zaagsma J: Eur J Pharmacol 153: 73 (1988).
23. Michel AD & Whiting RL: Eur J Pharmacol 145: 305 (1988).
24. Giraldo EH, Monferini H & Ladinsky: Eur J Pharmacol 141: 475 (1988).
25. Michel AD & Whiting RL: Eur J Pharmacol 176 197 (1990).
26. Levey AI: Life Sei 52: 441 (1993).
27. Maeda A, Kubo T, Mishina M & Numa S: FEES Letts 239: 339 (1988).
28. Thomas EA, Baker SA & Ehlert FJ: Mol Pharmacol 44: 102 (1993).
29. Reddy H, Watson N, Ford APDW & Eglen RM: Br J Pharmacol 114:49(1995).
30. Thomas EA & Ehlert FJ: J Pharmacol Exp Therap 271: 1042 (1994).
31. Fernandes LB, Fryer AD & Hirshman ÇA: J Pharmacol Exp Therap 262: 119(1992).
32. Watson N & Eglen RM: Br J Pharmacol 112: 179 (1994).
33. Watson N, Reddy H & Eglen RM: Eur J Pharmacol 278: 195 (1995).
34. Torphy TJ: J Pharmacol Exp Ther 227: 694 (1984).
35. Watson N, Magnussen H & Rabe KF: Eur J Pharmacol 275: 307 (1995).
36. Roffel AF, Meurs H, Elzinga CRS & Zaagsma J: Br J Pharmacol 115:665(1995).
37. Amsterdam RGM, van Meurs H, grower F, Postema J-B, Timmermans A & Zaagsma J: Eur J Pharmacol 172: 175 (1989).
38. Roffel AD, Elzinga CRS & Zaagsma J: Eur J Pharmacol 250: 267 (1993).
39. Chiarini A, Budresi R, Bolognesi ML, Minarini A & Melchiorre C: Br J Pharmacol 114: 1507 (1995).
40. Eglen RM, Michel AD & Whiting RL: Br J Pharmacol 96: 497 (1989).
41. Doods HN, Willim KD, Boddeke HWGM & Entzeroth M: Eur J Pharmacol 250: 223 (1993).
42. Pennefather JN, TA Gillman & F Mitchelson: Eur J Pharmacol 262: 297 (1994).
43. Eglen RM, Peele B, Pulido-Rios MT & Leung E: Br J Pharmacol, in press.
44. Doods HN: Drug News Perspectives 5: 345 (1992).
45. Andersson K-E: Pharmacol Revs 45: 253 (1993).
46. Oyasu H, Yamamoto T, Sato N, Ozaki R, Mukai T, Ozaki T, Nishii T, Sato H, Fujisawa T, Tozuka Z, Koibuchi Y, Honbo T, Esumi K, Ohtsuka M & Shimomura K Arzneim: Forsch/Drug Res 44: 1242 (1994).
47. Wallis RM, Burges RA, Cross PE, MacKenzie AR, Newgreen DT & Quinn P: Pharmacol Res 31 (supp): 54 (1995).
48. Kerr PM, Hillier K, Wallis RM & Garland CJ: Br J Pharmacol 115: 1518 (1995).